These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35712713)

  • 1. Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children.
    Jia X; Yin Z; Zhang W; Guo C; Du S; Zhang X
    Front Pharmacol; 2022; 13():902054. PubMed ID: 35712713
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.
    Wu XL; Long WM; Lu Q; Teng XQ; Qi TT; Qu Q; He GF; Qu J
    Front Pharmacol; 2022; 13():672543. PubMed ID: 35571125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study.
    Wu Z; Zhang S; Cao Y; Wang Q; Sun K; Zheng X
    Front Pharmacol; 2023; 14():1209063. PubMed ID: 37663252
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.
    Li L; Huang X; Liu J; Li C; Lin Z; Ren R; Zhang Y; Ding H; Chen J; Mao Y
    Infect Drug Resist; 2024; 17():3057-3071. PubMed ID: 39050834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.
    Cai Y; Leck H; Tan RW; Teo JQ; Lim TP; Lee W; Chlebicki MP; Kwa AL
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32726974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
    Liu S; Wu Y; Qi S; Shao H; Feng M; Xing L; Liu H; Gao Y; Zhu Z; Zhang S; Du Y; Lu Y; Yang J; Chen P; Sun T
    Crit Care; 2023 Jun; 27(1):232. PubMed ID: 37312218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection.
    Xia GL; Xu X; You XB; Wang X; Feng DD; Lei S; Jiang RL
    Ann Clin Microbiol Antimicrob; 2023 Nov; 22(1):101. PubMed ID: 37968642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections.
    Xia GL; Jiang RL
    BMC Infect Dis; 2021 Oct; 21(1):1034. PubMed ID: 34607561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of Polymyxin B Nephrotoxicity and Its Precursors in the Intensive Care Unit: A Retrospective Cohort Study.
    Özkarakaş H; Özdemir Y; Tosun S; Tekgül ZT; Bilgin MU; Özmuk O; Çalık B
    Cureus; 2023 Aug; 15(8):e44301. PubMed ID: 37779820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant
    Jia X; Yin Z; Zhang W; Du S
    Infect Drug Resist; 2023; 16():4177-4187. PubMed ID: 37396067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.
    Siddiqui NU; Qamar FN; Jurair H; Haque A
    BMC Infect Dis; 2014 Nov; 14():626. PubMed ID: 25430979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.
    Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J
    Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
    Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS
    J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.
    Qu J; Qi TT; Qu Q; Long WM; Chen Y; Luo Y; Wang Y
    Infect Drug Resist; 2022; 15():1205-1218. PubMed ID: 35345474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia.
    Zeng H; Zeng Z; Kong X; Zhang H; Chen P; Luo H; Chen Y
    Front Pharmacol; 2020; 11():579069. PubMed ID: 33613276
    [No Abstract]   [Full Text] [Related]  

  • 17. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia].
    Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA
    Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study.
    Jin J; Zhu J; Zhu Z; Kim WY; O'Rourke J; Lin Z; Chen M
    Ann Transl Med; 2022 Oct; 10(20):1137. PubMed ID: 36388829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria.
    Tuon FF; Rocha JL; Gasparetto J
    J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Carbapenem-Resistant Multidrug-Resistant Gram-Negative Bacilli with Intracerebroventricular Injection of Polymyxin B: A Retrospective Study.
    Liu D; Niu J; Chen G; Xu L
    Infect Drug Resist; 2022; 15():7653-7666. PubMed ID: 36579127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.